Abstract 1359
Background
Across the most commonly diagnosed cancers (breast, colorectal, lung and prostate), advances in curative treatment have led to improvements in cancer survival. Workplace policies for medical leave however, may have been instituted when surgery alone was sufficient treatment for cancer. The duration of adjuvant therapy may not be incorporated into laws providing temporary financial assistance or protecting patients from workplace dismissal. Our objective is to determine the median duration of curative treatment and recovery time for the four common cancers and to understand the implications in the broader context.
Methods
BC Cancer provides cancer care for a population of 4.6 million. A retrospective review was completed of referred patients from 2010-2016, ≤ 65 years old, newly diagnosed with stage I-III breast, colorectal, lung, prostate cancer, received curative intent treatment that includes either chemotherapy or radiotherapy. Information was collected on baseline characteristics, date of diagnosis, surgical procedure and date, radiotherapy type, duration and intent (neoadjuvant/ concurrent/ adjuvant), chemotherapy type, duration and intent.
Results
26,995 patients were included in the study, 11,911 (44%) received definitive radiotherapy or multimodality treatment.Table: 1655P
Breast N = 12706 | Prostate N = 6360 | Colorectal N = 5336 | Lung N = 2593 | |
---|---|---|---|---|
No adjuvant treatment | 4605 | 5377 | 3491 | 1611 |
Definitive radiation or multimodality treatment | 8101 | 983 | 1845 | 982 |
Median time from diagnosis to definitive treatment (weeks) | 5.14 | 13.71 | 4.29 | 5.42 |
Median time between definitive treatment and adjuvant therapy (weeks) | 8.14 | 18.14 | 8.42 | 8.57 |
Median duration of adjuvant chemotherapy (weeks) | 14.29 | N/A | 20.00 | 10.00 |
Median duration of adjuvant radiation +/- chemotherapy (weeks) | 3.85 | 6.71 | 5.00 | 5.57 |
Median duration of definitive radiation +/- chemotherapy (weeks) | N/A | 6.42 | N/A | 6.42 |
Median duration from definitive treatment to completion of all treatment (weeks) | 23.57 | 6.85 | 28.29 | 18.00/6.14* *chemo/xrt |
Conclusions
Almost half of patients who undergo curative cancer treatment require definitive radiotherapy or multimodality treatment. The median duration of therapy varies widely depending on primary site and modality (6.14 - 28.29 weeks). This has implications for financial support such as United Kingdom’s Statutory Sick Pay (28 weeks) and Canada Employment Insurance (15 weeks), as well as workplace dismissal in the United States where the Family and Medical Leave Act protects employees for 12 weeks absence. Governments should consider amending the laws to reflect current cancer treatment durations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Ho: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Travel / Accommodation / Expenses: Pfizer ; Honoraria (self): BMS; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): Lilly; Research grant / Funding (self): Genzyme; Honoraria (self), Research grant / Funding (self): Eisai; Honoraria (self): Merck; Honoraria (self): Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract